世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

がん/腫瘍プロファイリング市場：技術（イムノアッセイ、NGS、PCR）、がんタイプ（乳がん、肺がん、大腸がん）、バイオマーカータイプ（ゲノムバイオマーカー、タンパク質バイオマーカー）、アプリケーション（バイオマーカー探索、診断、予後診断）- 2027年までの世界予測


Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027

がん/腫瘍プロファイリングの世界市場は、2022年の97億米ドルから2027年には160億米ドルに達すると予測され、予測期間中のCAGRは10.6%となります。この市場の成長は、がん研究への資金投入の増加やプロファイリン... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年11月8日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		295 343 英語

　

サマリー

がん/腫瘍プロファイリングの世界市場は、2022年の97億米ドルから2027年には160億米ドルに達すると予測され、予測期間中のCAGRは10.6%となります。この市場の成長は、がん研究への資金投入の増加やプロファイリング技術の技術的進歩が主な要因となっています。また、個別化医療への嗜好の高まりやポイントオブケア診断のニーズの高まりは、予測期間中に市場関係者に大きな成長機会を提供すると期待されています。一方、サンプルの採取や保管に関する技術的な問題は、市場の成長をある程度抑制する要因となっています。


技術別では、がん/腫瘍プロファイリング市場でイムノアッセイセグメントが最大の市場シェアを占めている
がん/腫瘍プロファイリング市場は、技術別に、イムノアッセイ、in situハイブリダイゼーション、次世代シーケンサー（NGS）、ポリメラーゼ連鎖反応（PCR）、質量分析、マイクロアレイ、その他の技術に区分される。2021年には、イムノアッセイセグメントが最大の市場シェアを占めた。この大きなシェアは、がんの診断と予後に使用され、適切な治療の決定を支援し、サンプル中の分析物の存在と濃度を測定するためのゴールドスタンダードとしてこれらのアッセイが採用されていることに起因している可能性があります。


癌のタイプ別では、肺癌分野が予測期間中に最も高いCAGRを記録すると予想される
がんの種類に基づき、がん/腫瘍プロファイリング市場は、乳がん、肺がん、大腸がん、前立腺がん、メラノーマ、その他のがんに区分されます。予測期間中は、肺がん分野が最も高いCAGRを記録すると予想されます。これは、早期診断の必要性の高まりと、肺がんの罹患率の高さに起因しています。


バイオマーカータイプ別では、予測期間中にゲノムバイオマーカーセグメントが最大のシェアを占めた
バイオマーカータイプに基づき、世界のがん/腫瘍プロファイリング市場は、ゲノムバイオマーカーとタンパク質バイオマーカーに区分されます。2021年、ゲノムバイオマーカーセグメントは、がん/腫瘍プロファイリング市場で最大のシェアを占めた。このセグメントの大きなシェアは、ハイスループット技術の進歩と、がん診断および予後の際にこれらのバイオマーカーが多く採用されていることに起因しています。


用途別では、研究用途のセグメントが予測期間中に最大の市場シェアを占める
アプリケーションに基づき、がん/腫瘍プロファイリング市場は研究アプリケーションと臨床アプリケーションに区分されます。2021年には、研究用途ががん/腫瘍プロファイリング市場で最大のシェアを占め、臨床用途がそれに続いた。研究用途のシェアが大きいのは、個別化医療の分野が急速に拡大していることと、がん研究への資金提供が増加していることに起因しています。


2021年、がん/腫瘍プロファイリング市場で北米が最大シェアを占める見込み
2021年のがん/腫瘍プロファイリング市場では、北米が最大のシェアを占め、次いで欧州、アジア太平洋、中南米、中東・アフリカの順となりました。この市場セグメントの大きなシェアは、バイオマーカーの発見と開発のための投資の増加、個別化治療の需要の高まり、がん研究のための高度なオミックス技術の採用の高まりに起因していると考えられます。

主な参加企業の内訳は、以下の通りです。
- 企業タイプ別：Tier 1-35%、Tier 2-45%、Tier 3-20
- 役職別：Cレベル-35％、ディレクターレベル-25％、その他-40
- 地域別：北米45％、欧州30％、アジア太平洋20％、中南米5％、中近東・アフリカ5

がん/腫瘍プロファイリング市場の主要プレイヤー
がん/腫瘍プロファイリング市場で活動する主要なプレーヤーは、Illumina, Inc.（米国）、QIAGEN N.V.（ドイツ）、NeoGenomics Laboratories, Inc.（米国）、シスメックス株式会社（日本）、HTG Molecular Diagnostics, Inc（米国）、Helomics Corporation（米国）、Caris Life Sciences（米国）、NanoString Technologies, Inc（米国）、Guardant Health, Inc（米国）および Foundation Medicine（米国）です。

調査対象範囲
本レポートでは、がん/腫瘍プロファイリングを分析し、技術、がんタイプ、バイオマーカータイプ、アプリケーション、地域などの様々なセグメントに基づいて、この市場の市場規模および将来の成長性を推定することを目的としています。また、市場で入手可能な様々な癌/腫瘍プロファイリング企業の製品ポートフォリオマトリックスも掲載しています。また、本市場の主要企業の競合分析、企業プロファイル、製品提供、主要な市場戦略も掲載しています。
本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や中小企業も市場の脈拍を測ることができ、ひいては市場のより重要なシェアを獲得するのに役立つことでしょう。本レポートを購入された企業は、下記の戦略のいずれか、または組み合わせて使用することで、市場での地位を強化することができます。
本レポートでは、以下のポイントについて考察しています。
- 市場浸透度。世界の癌/腫瘍プロファイリング市場におけるトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場を技術、がんタイプ、バイオマーカータイプ、アプリケーション、地域別に分析しています。
- 製品の強化/革新。世界の癌/腫瘍プロファイリング市場における今後の動向と製品発売に関する詳細な洞察
- 市場開発。技術、癌タイプ、バイオマーカータイプ、アプリケーション、地域ごとの有利な新興市場に関する包括的な情報
- 市場の多様化。新製品や製品の強化、成長地域、最近の開発、世界のがん/腫瘍プロファイリング市場における投資に関する徹底的な情報
- 競争力の評価。世界の癌/腫瘍プロファイリング市場における主要企業の市場シェア、成長戦略、製品オファリング、競合のリーダーシップマッピング、能力に関する詳細な評価。

ページTOPに戻る


目次

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS & EXCLUSIONS 39
1.2.2 MARKETS COVERED 40
FIGURE 1 CANCER/TUMOR PROFILING MARKET 40
1.2.3 YEARS CONSIDERED 41
1.3 CURRENCY CONSIDERED 41
TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS: 41
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH APPROACH 43
FIGURE 2 RESEARCH DESIGN 43
2.1.1 SECONDARY RESEARCH 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY RESEARCH 45
FIGURE 3 PRIMARY SOURCES 45
2.1.2.1 Key data from primary sources 46
2.1.2.2 Insights from primary experts 47
2.1.2.3 Breakdown of primaries 47
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
2.2 MARKET SIZING & VALIDATION APPROACH 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS 49
FIGURE 7 TOP-DOWN APPROACH 50
FIGURE 8 CAGR PROJECTIONS 51
FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 51
2.3 DATA TRIANGULATION APPROACH 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.4 MARKET SHARE ESTIMATION 54
2.5 STUDY ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
 
2.7 RISK ASSESSMENT 55
TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET 55
3 EXECUTIVE SUMMARY 56
FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 56
FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION) 57
FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) 58
FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 58
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET 59
4 PREMIUM INSIGHTS 61
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW 61
FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 61
4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021) 62
FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 62
4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022–2027) 64
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 64
4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027) 65
FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
5.2.1 DRIVERS 67
5.2.1.1 Rising incidence of cancer 67
FIGURE 22 GLOBAL CANCER INCIDENCE, 2008–2030 67
5.2.1.2 Increasing use of biomarkers in cancer profiling 67
5.2.1.3 Growing investments in cancer research 68
5.2.1.4 Technological advancements in cancer profiling techniques 69
5.2.2 RESTRAINTS 69
5.2.2.1 High capital investments for biomarker discovery & development 69
 
TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT 70
5.2.2.2 Technical issues related to sample collection & storage 70
5.2.3 OPPORTUNITIES 71
5.2.3.1 Growing preference for personalized medicine 71
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021 71
5.2.3.2 Rising need for point-of-care diagnostics 72
TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE) 72
5.2.4 CHALLENGES 73
5.2.4.1 Low biomarker discovery-to-approval ratio 73
FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS 73
5.2.4.2 Poor regulatory and reimbursement scenario 74
TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.3 INDUSTRY TRENDS 75
5.3.1 INTEGRATION OF OMICS DATA 76
TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES 76
5.3.2 ADVANCES IN LIQUID BIOPSY 77
5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE 78
TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021) 78
5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES 79
6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY 80
6.1 INTRODUCTION 81
TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 81
TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027(USD MILLION) 82
6.2 IMMUNOASSAYS 82
6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET 82
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018–2021 (USD MILLION) 83
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2027 (USD MILLION) 84
6.3 NEXT-GENERATION SEQUENCING 84
6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET 84
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018–2021 (USD MILLION) 86
TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2027 (USD MILLION) 86
 
6.4 POLYMERASE CHAIN REACTION 87
6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION TO DRIVE MARKET 87
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2021 (USD MILLION) 88
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2027 (USD MILLION) 89
6.5 IN SITU HYBRIDIZATION 89
6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET 89
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018–2021 (USD MILLION) 90
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2027 (USD MILLION) 91
6.6 MICROARRAYS 91
6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET 91
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018–2021 (USD MILLION) 92
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2027 (USD MILLION) 93
6.7 MASS SPECTROMETRY 93
6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET 93
TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018–2021 (USD MILLION) 94
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2027 (USD MILLION) 95
6.8 OTHER TECHNOLOGIES 95
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2021 (USD MILLION) 96
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 96
7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE 97
7.1 INTRODUCTION 98
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 98
TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 98
7.2 BREAST CANCER 99
7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET 99
TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 99
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 100
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 101
 
7.3 LUNG CANCER 101
7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET 101
FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012−2030 102
TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 103
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 104
7.4 COLORECTAL CANCER 104
7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET 104
FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018) 105
TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 106
TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 106
7.5 PROSTATE CANCER 107
7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET 107
FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020) 107
TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 108
TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 108
7.6 MELANOMA 109
7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS TO DRIVE MARKET 109
TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 109
TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018–2021 (USD MILLION) 110
TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022–2027 (USD MILLION) 110
7.7 OTHER CANCERS 111
FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020) 111
TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018–2021 (USD MILLION) 112
TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 112
8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE 113
8.1 INTRODUCTION 114
TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 114
TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 114
 
8.2 GENETIC BIOMARKERS 115
8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES 115
TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 116
TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 116
8.3 PROTEIN BIOMARKERS 117
8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS 117
TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 118
TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 118
8.4 OTHER BIOMARKERS 119
TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 119
TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 120
9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 122
TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022–2027 (USD MILLION) 122
9.2 RESEARCH APPLICATIONS 122
TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 123
TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 123
TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 124
TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 124
9.2.1 BIOMARKER DISCOVERY 125
9.2.1.1 Development of personalized medicine and drug development to support market 125
TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018–2021 (USD MILLION) 125
TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022–2027 (USD MILLION) 126
9.2.2 PERSONALIZED MEDICINE 126
9.2.2.1 Rising funding activities in precision medicine to support market 126
TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018–2021 (USD MILLION) 127
TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2027 (USD MILLION) 128
 
9.3 CLINICAL APPLICATIONS 128
TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 129
TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 129
TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 130
TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 130
9.3.1 DIAGNOSTICS 131
9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market 131
TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 132
TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 132
9.3.2 PROGNOSTICS 133
9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling 133
TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 133
TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 134
9.3.3 MONITORING & TREATMENT 134
9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market 134
TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018–2021 (USD MILLION) 135
TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022–2027 (USD MILLION) 135
9.3.4 SCREENING 136
9.3.4.1 Screening tests to help high-risk patients ascertain outcomes 136
TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018–2021 (USD MILLION) 136
TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022–2027 (USD MILLION) 137
10 CANCER/TUMOR PROFILING MARKET, BY REGION 138
10.1 INTRODUCTION 139
FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021) 139
TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018–2021 (USD MILLION) 140
TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022–2027 (USD MILLION) 140
10.2 NORTH AMERICA 140
TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020) 141
FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 142
FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT 143
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 143
TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 144
TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 144
TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 145
TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 145
TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 146
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 146
TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 146
TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 147
TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 148
10.2.1 US 148
10.2.1.1 High R&D investments for cancer biomarker research to drive market 148
TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 149
TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 149
TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 150
TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 150
TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 150
TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 151
TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 151
TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 151
TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 152
TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
10.2.2 CANADA 153
10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market 153
TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 154
TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 154
TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 154
TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 155
TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 155
TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 155
TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 156
TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 156
TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 156
TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 157
TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 157
10.3 EUROPE 157
FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 158
TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 159
TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 159
TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 160
TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 160
TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 161
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 161
TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 161
TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 162
TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 162
TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 162
TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 163
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 163
10.3.1 GERMANY 163
10.3.1.1 Favorable government health policies to drive market 163
TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 164
TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 164
TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 165
TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 165
TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 166
TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 166
TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 166
TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 167
TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 168
10.3.2 UK 168
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market 168
TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 169
TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 169
TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 169
TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 170
TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 170
TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 170
TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 171
TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 171
TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 171
TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 172
TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 172
10.3.3 FRANCE 172
10.3.3.1 Growing government investments in genomics & proteomics research to drive market 172
TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 173
TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 173
TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 174
TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 174
TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 175
TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 175
TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 175
TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 176
TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 177
10.3.4 ITALY 177
10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market 177
TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 178
TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 178
TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 179
TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 179
TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 180
TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 180
TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 181
TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 181
TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 181
TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 182
TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 182
10.3.5 SPAIN 182
10.3.5.1 Rising incidence of cancer to drive demand for biomarkers 182
TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 183
TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 183
TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 184
TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 184
TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 185
TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 185
TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 185
TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 186
TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 187
10.3.6 REST OF EUROPE (ROE) 187
TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 188
TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 188
TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 189
TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 189
TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 189
TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 190
TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 190
TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 190
TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 191
TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 191
10.4 ASIA PACIFIC 191
FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 192
FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT 193
TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 194
TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 194
TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 194
TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 195
TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 195
TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 196
TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 196
TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 196
TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022–2027 (USD MILLION) 197
TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 198
10.4.1 JAPAN 198
10.4.1.1 Increasing initiatives to boost genomic research to support market 198
TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 199
TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 199
TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 200
TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 200
TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 201
TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 201
TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 201
TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 202
TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 203
10.4.2 CHINA 203
10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products 203
TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 204
TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 204
TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 204
TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 205
TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 205
TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 205
TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 206
TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 206
TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 206
TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 207
TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 207
10.4.3 INDIA 207
10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market 207
TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 208
TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 208
TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 209
TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 209
TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 210
TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 210
TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 210
TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 211
TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 212
10.4.4 REST OF ASIA PACIFIC (ROAPAC) 212
TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 213
TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 213
TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 214
TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 214
TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 214
TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 215
TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 215
TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 215
TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 216
TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 216

　

ページTOPに戻る


　

Summary

The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.


Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market
Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.


Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period
Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.


Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period
Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.


Based on applications, the research application segment holds the largest market share during the forecast period
Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.


North America is expected to account for the largest share of the cancer/tumor profiling market in 2021
In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa–5%

Key players in cancer/tumor profiling the market
The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).

Research Coverage:
The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
• Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS & EXCLUSIONS 39
1.2.2 MARKETS COVERED 40
FIGURE 1 CANCER/TUMOR PROFILING MARKET 40
1.2.3 YEARS CONSIDERED 41
1.3 CURRENCY CONSIDERED 41
TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS: 41
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH APPROACH 43
FIGURE 2 RESEARCH DESIGN 43
2.1.1 SECONDARY RESEARCH 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY RESEARCH 45
FIGURE 3 PRIMARY SOURCES 45
2.1.2.1 Key data from primary sources 46
2.1.2.2 Insights from primary experts 47
2.1.2.3 Breakdown of primaries 47
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
2.2 MARKET SIZING & VALIDATION APPROACH 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS 49
FIGURE 7 TOP-DOWN APPROACH 50
FIGURE 8 CAGR PROJECTIONS 51
FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 51
2.3 DATA TRIANGULATION APPROACH 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.4 MARKET SHARE ESTIMATION 54
2.5 STUDY ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
 
2.7 RISK ASSESSMENT 55
TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET 55
3 EXECUTIVE SUMMARY 56
FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 56
FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION) 57
FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) 58
FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 58
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET 59
4 PREMIUM INSIGHTS 61
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW 61
FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 61
4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021) 62
FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 62
4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022–2027) 64
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 64
4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027) 65
FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
5.2.1 DRIVERS 67
5.2.1.1 Rising incidence of cancer 67
FIGURE 22 GLOBAL CANCER INCIDENCE, 2008–2030 67
5.2.1.2 Increasing use of biomarkers in cancer profiling 67
5.2.1.3 Growing investments in cancer research 68
5.2.1.4 Technological advancements in cancer profiling techniques 69
5.2.2 RESTRAINTS 69
5.2.2.1 High capital investments for biomarker discovery & development 69
 
TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT 70
5.2.2.2 Technical issues related to sample collection & storage 70
5.2.3 OPPORTUNITIES 71
5.2.3.1 Growing preference for personalized medicine 71
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021 71
5.2.3.2 Rising need for point-of-care diagnostics 72
TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE) 72
5.2.4 CHALLENGES 73
5.2.4.1 Low biomarker discovery-to-approval ratio 73
FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS 73
5.2.4.2 Poor regulatory and reimbursement scenario 74
TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.3 INDUSTRY TRENDS 75
5.3.1 INTEGRATION OF OMICS DATA 76
TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES 76
5.3.2 ADVANCES IN LIQUID BIOPSY 77
5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE 78
TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021) 78
5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES 79
6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY 80
6.1 INTRODUCTION 81
TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 81
TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027(USD MILLION) 82
6.2 IMMUNOASSAYS 82
6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET 82
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018–2021 (USD MILLION) 83
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2027 (USD MILLION) 84
6.3 NEXT-GENERATION SEQUENCING 84
6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET 84
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018–2021 (USD MILLION) 86
TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2027 (USD MILLION) 86
 
6.4 POLYMERASE CHAIN REACTION 87
6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION TO DRIVE MARKET 87
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2021 (USD MILLION) 88
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2027 (USD MILLION) 89
6.5 IN SITU HYBRIDIZATION 89
6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET 89
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018–2021 (USD MILLION) 90
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2027 (USD MILLION) 91
6.6 MICROARRAYS 91
6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET 91
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018–2021 (USD MILLION) 92
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2027 (USD MILLION) 93
6.7 MASS SPECTROMETRY 93
6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET 93
TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018–2021 (USD MILLION) 94
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2027 (USD MILLION) 95
6.8 OTHER TECHNOLOGIES 95
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2021 (USD MILLION) 96
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 96
7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE 97
7.1 INTRODUCTION 98
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 98
TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 98
7.2 BREAST CANCER 99
7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET 99
TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 99
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 100
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 101
 
7.3 LUNG CANCER 101
7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET 101
FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012−2030 102
TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 103
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 104
7.4 COLORECTAL CANCER 104
7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET 104
FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018) 105
TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 106
TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 106
7.5 PROSTATE CANCER 107
7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET 107
FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020) 107
TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018–2021 (USD MILLION) 108
TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2027 (USD MILLION) 108
7.6 MELANOMA 109
7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS TO DRIVE MARKET 109
TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 109
TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018–2021 (USD MILLION) 110
TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022–2027 (USD MILLION) 110
7.7 OTHER CANCERS 111
FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020) 111
TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018–2021 (USD MILLION) 112
TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022–2027 (USD MILLION) 112
8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE 113
8.1 INTRODUCTION 114
TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 114
TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 114
 
8.2 GENETIC BIOMARKERS 115
8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES 115
TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 116
TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 116
8.3 PROTEIN BIOMARKERS 117
8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS 117
TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 118
TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 118
8.4 OTHER BIOMARKERS 119
TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018–2021 (USD MILLION) 119
TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022–2027 (USD MILLION) 120
9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 122
TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022–2027 (USD MILLION) 122
9.2 RESEARCH APPLICATIONS 122
TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 123
TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 123
TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 124
TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 124
9.2.1 BIOMARKER DISCOVERY 125
9.2.1.1 Development of personalized medicine and drug development to support market 125
TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018–2021 (USD MILLION) 125
TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022–2027 (USD MILLION) 126
9.2.2 PERSONALIZED MEDICINE 126
9.2.2.1 Rising funding activities in precision medicine to support market 126
TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018–2021 (USD MILLION) 127
TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2027 (USD MILLION) 128
 
9.3 CLINICAL APPLICATIONS 128
TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 129
TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 129
TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018–2021 (USD MILLION) 130
TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2027 (USD MILLION) 130
9.3.1 DIAGNOSTICS 131
9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market 131
TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 132
TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 132
9.3.2 PROGNOSTICS 133
9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling 133
TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018–2021 (USD MILLION) 133
TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022–2027 (USD MILLION) 134
9.3.3 MONITORING & TREATMENT 134
9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market 134
TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018–2021 (USD MILLION) 135
TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022–2027 (USD MILLION) 135
9.3.4 SCREENING 136
9.3.4.1 Screening tests to help high-risk patients ascertain outcomes 136
TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018–2021 (USD MILLION) 136
TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022–2027 (USD MILLION) 137
10 CANCER/TUMOR PROFILING MARKET, BY REGION 138
10.1 INTRODUCTION 139
FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021) 139
TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018–2021 (USD MILLION) 140
TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022–2027 (USD MILLION) 140
10.2 NORTH AMERICA 140
TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020) 141
FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 142
FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT 143
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 143
TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 144
TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 144
TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 145
TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 145
TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 146
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 146
TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 146
TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 147
TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 148
10.2.1 US 148
10.2.1.1 High R&D investments for cancer biomarker research to drive market 148
TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 149
TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 149
TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 150
TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 150
TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 150
TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 151
TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 151
TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 151
TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 152
TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 152
10.2.2 CANADA 153
10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market 153
TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 154
TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 154
TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 154
TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 155
TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 155
TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 155
TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 156
TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 156
TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 156
TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 157
TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 157
10.3 EUROPE 157
FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 158
TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 159
TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 159
TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 160
TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 160
TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 161
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 161
TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 161
TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 162
TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 162
TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 162
TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 163
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 163
10.3.1 GERMANY 163
10.3.1.1 Favorable government health policies to drive market 163
TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 164
TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 164
TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 165
TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 165
TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 166
TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 166
TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 166
TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 167
TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 167
TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 168
10.3.2 UK 168
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market 168
TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 169
TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 169
TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 169
TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 170
TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 170
TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 170
TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 171
TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 171
TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 171
TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 172
TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 172
10.3.3 FRANCE 172
10.3.3.1 Growing government investments in genomics & proteomics research to drive market 172
TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 173
TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 173
TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 174
TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 174
TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 175
TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 175
TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 175
TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 176
TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 176
TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 177
10.3.4 ITALY 177
10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market 177
TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 178
TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 178
TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 179
TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 179
TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 180
TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 180
TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 181
TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 181
TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 181
TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 182
TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 182
10.3.5 SPAIN 182
10.3.5.1 Rising incidence of cancer to drive demand for biomarkers 182
TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 183
TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 183
TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 184
TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 184
TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 185
TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 185
TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 185
TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 186
TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 186
TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 187
10.3.6 REST OF EUROPE (ROE) 187
TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 188
TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 188
TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 189
TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 189
TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 189
TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 190
TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 190
TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 190
TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 191
TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 191
10.4 ASIA PACIFIC 191
FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 192
FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT 193
TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 194
TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022–2027 (USD MILLION) 194
TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 194
TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 195
TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 195
TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 196
TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 196
TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 196
TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022–2027 (USD MILLION) 197
TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 197
TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 198
10.4.1 JAPAN 198
10.4.1.1 Increasing initiatives to boost genomic research to support market 198
TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 199
TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 199
TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 200
TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 200
TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 201
TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 201
TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 201
TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 202
TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 202
TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 203
10.4.2 CHINA 203
10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products 203
TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040 204
TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 204
TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 204
TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 205
TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 205
TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 205
TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 206
TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 206
TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 206
TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 207
TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 207
10.4.3 INDIA 207
10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market 207
TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 208
TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 208
TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 209
TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 209
TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 210
TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 210
TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 210
TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 211
TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 211
TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 212
10.4.4 REST OF ASIA PACIFIC (ROAPAC) 212
TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018–2021 (USD MILLION) 213
TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022–2027 (USD MILLION) 213
TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018–2021 (USD MILLION) 214
TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022–2027 (USD MILLION) 214
TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018–2021 (USD MILLION) 214
TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022–2027 (USD MILLION) 215
TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 215
TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 215
TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018–2021 (USD MILLION) 216
TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 216

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のバイオ薬物分野での最新刊レポート

本レポートと同じKEY WORD（biomarker）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14　10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.